Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive breast cancer cells to trastuzumab

@article{Goldblatt2008LipidconjugatedTT,
  title={Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive breast cancer cells to trastuzumab},
  author={Erin M. Goldblatt and Priscilla A Erickson and Erin R. Gentry and Sergei M. Gryaznov and Brittney-Shea Herbert},
  journal={Breast Cancer Research and Treatment},
  year={2008},
  volume={118},
  pages={21-32}
}
HER2 amplification in breast cancer is associated with a more aggressive disease, greater likelihood of recurrence, and decreased survival compared to women with HER2-negative breast cancer. Trastuzumab is a monoclonal antibody that inhibits HER2 activity, making this compound an important therapeutic option for patients with HER2-positive breast cancer. However, resistance to trastuzumab develops rapidly in a large number of breast cancer patients. The objective of this study was to determine… CONTINUE READING